0001628171 2026-04-15 2026-04-15 0001628171 1 2026-04-15 2026-04-15 0001628171 2 2026-04-15 2026-04-15 iso4217:USD pure shares S-3 424B5 EX-FILING FEES 333-277640 0001628171 Revolution Medicines, Inc. N/A N/A S-3 Revolution Medicines, Inc. false Debt Convertible into Equity 0.50% Convertible Senior Notes due 2033 true 500000000 500000000.00 0.0001381 69050.00 false Equity Common Stock, $0.0001 par value per share true 0.0001381 0.00 500000000.00 69050.00 0.00 0.00 69050.00 Note 1.a. The amount registered is $500,000,000, which represents the aggregate principal amount of 0.50% Convertible Senior Notes due 2033 (the "Notes") whose offer and sale are registered by the registration statement relating to the prospectus supplement to which this exhibit is attached. Note 1.b. The amount set forth in the column titled "Proposed Maximum Offering Price Per Unit" represents proposed maximum offering price per $1,000 principal amount of Notes. Note 3.a. The fee payable in connection with the offering relating to this exhibit has been calculated pursuant to Rule 457(r) under the Securities Act and paid in accordance with Rule 456(b) under the Securities Act. Note 2.a. The amount registered includes an indeterminate number of shares of Common Stock, $0.0001 par value per share (the "Common Stock"), of Revolution Medicines, Inc. issuable upon conversion of the Notes. The initial maximum conversion rate of the Notes is 7.0422 shares of Common Stock per $1,000 principal amount of Notes. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the amount of shares of Common Stock whose offer and sale is registered by the registration statement relating to the prospectus supplement to which this exhibit is attached includes an indeterminate number of shares of Common Stock that may be issued in connection with stock splits, stock dividends, or similar transactions. No additional consideration will be received in connection with the exercise of the conversion privilege of the Notes. Note 2.b. Pursuant to Rule 457(i) under the Securities Act, no separate registration fee is required for the shares of Common Stock issuable upon conversion of the Notes because no additional consideration is to be received in connection with the exercise of the conversion privilege of the Notes. Note 3.a. The fee payable in connection with the offering relating to this exhibit has been calculated pursuant to Rule 457(r) under the Securities Act and paid in accordance with Rule 456(b) under the Securities Act. 500000000.00 true